Gradalis Inc. in Texas have shown a survival advantage x 5 compared to controls in humans in a phase I clinical trial using RNAi in various advanced cancers, with 7 patients still alive after 2 - 3 years.  They are currently conducting three phase 2 clinical trials and seeing similar results.  These trials use expressed RNAi (shRNA) instead of siRNA, that Alnylam focus on.   The expressed RNAi foundation patents are owned by Benitec Biopharma in Australia, who last year combined RNAi in dentritic cells to target arthritis, showing excellent results in mice.   Thousands of pre-clinical in-vivo and ex-vivo studies published using shRNA without the delivery problems encountered by siRNA.  With a market cap of 1/60th of Alnylam, and equally important IP, they appear very under the radar.